Treatment of Cannabis Use Disorder: Current Science and Future Outlook

Pharmacotherapy

Volumn 36, Issue 5, 2016, Pages 511-535

  Sherman, Brian J ^a   McRae Clark, Aimee L ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

cannabis; cannabis use disorder; intervention; marijuana; pharmacotherapy; psychotherapy; review; treatment

Indexed keywords

ACETYLCYSTEINE; AMFEBUTAMONE; ATOMOXETINE; BACLOFEN; BUSPIRONE; DRONABINOL; ESCITALOPRAM; GABAPENTIN; LITHIUM CARBONATE; LOFEXIDINE; MIRTAZAPINE; NABILONE; NEFAZODONE; PLACEBO; QUETIAPINE; VALPROATE SEMISODIUM; VENLAFAXINE; ZOLPIDEM; 4 AMINOBUTYRIC ACID; AMINE; CYCLOHEXANECARBOXYLIC ACID DERIVATIVE;

ABSTINENCE; ARTICLE; ATTENTION DEFICIT DISORDER; CANNABIS ADDICTION; CANNABIS USE; COGNITIVE THERAPY; COMORBIDITY; COMPUTER ASSISTED THERAPY; CONTINGENCY MANAGEMENT; DEPRESSION; DRUG DOSE COMPARISON; DRUG POTENTIATION; FAMILY THERAPY; HELP SEEKING BEHAVIOR; HUMAN; IRRITABILITY; MINDFULNESS; MOTIVATIONAL ENHANCEMENT THERAPY; MOTIVATIONAL INTERVIEWING; NONHUMAN; PSYCHOMOTOR PERFORMANCE; PSYCHOPHARMACOTHERAPY; PSYCHOTHERAPY; RELAPSE; SIDE EFFECT; SLEEP DISORDER; SOCIAL INTERACTION; UNSPECIFIED SIDE EFFECT; WITHDRAWAL SYNDROME; HEALTH CARE DELIVERY; MARIJUANA ABUSE;

ACETYLCYSTEINE; AMINES; CYCLOHEXANECARBOXYLIC ACIDS; GAMMA-AMINOBUTYRIC ACID; HEALTH SERVICES ACCESSIBILITY; HUMANS; MARIJUANA ABUSE; PSYCHOTHERAPY;

EID: 84969962210     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/phar.1747     Document Type: Article

References (100)

1. SAMHSA Results from the 2013 National Survey on Drug Use and Health: Summary of National Findings. NSDUH Series H-48, HHS, Publication No (SMA) 14-4863 2014. "Government Document"
2. van der Pol P, Liebregts N, de Graaf R, Korf DJ, van den Brink W, van Laar M,. The Dutch Cannabis Dependence (CanDep) study on the course of frequent cannabis use and dependence: objectives, methods and sample characteristics. Int J Methods Psychiatr Res 2011; 3: 169-81.
3. Anthony JC, Warner LA, Kessler RC,. Comparative epidemiology of dependence on tobacco, alcohol, controlled substances, and inhalants: basic findings from the National Comorbidity Survey. Exp Clin Psychopharmacol 1994; 3: 244-68.
4. Radhakrishnan R, Wilkinson ST, D'Souza DC,. Gone to pot-a review of the association between cannabis and psychosis. Front Psychiatry 2014; 5: 1-24.
5. Crane N, Schuster R, Fusar-Poli P, Gonzalez R,. Effects of cannabis on neurocognitive functioning: recent advances, neurodevelopmental influences, and sex differences. Neuropsychol Rev 2013; 2: 117-37.
6. Fergusson DM, Boden JM,. Cannabis use and later life outcomes. Addiction 2008; 6: 969-76.
7. Patton GC, Coffey C, Carlin JB, Degenhardt L, Lynskey M, Hall W,. Cannabis use and mental health in young people: cohort study. Br Med J 2002; 7374: 1195-8.
8. American Psychiatric A, American Psychiatric A, Force DSMT. Diagnostic and statistical manual of mental disorders: DSM-5. Washington, DC: American Psychiatric Association; 2013.
9. Pew Research C. Debate over legalizing marijuana, disagreement over drug's dangers. 2015. "Online Multimedia"
10. Budney AJ, Moore BA, Rocha HL, Higgins ST,. Clinical trial of abstinence-based vouchers and cognitive-behavioral therapy for cannabis dependence. J Consult Clin Psychol 2006; 2: 307-16.
11. Kadden RM, Litt MD, Kabela-Cormier E, Petry NM,. Abstinence rates following behavioral treatments for marijuana dependence. Addict Behav 2007; 6: 1220-36.
12. Marijuana Treatment Project Research G. Brief treatments for cannabis dependence: findings from a randomized multisite trial. J Consult Clin Psychol 2004; 3: 455-66.
13. Budney AJ, Higgins ST, Radonovich KJ, Novy PL,. Adding voucher-based incentives to coping skills and motivational enhancement improves outcomes during treatment for marijuana dependence. J Consult Clin Psychol 2000; 6: 1051-61.
14. Carroll KM, Nich C, Lapaglia DM, Peters EN, Easton CJ, Petry NM,. Combining cognitive behavioral therapy and contingency management to enhance their effects in treating cannabis dependence: less can be more, more or less. Addiction 2012; 9: 1650-9.
15. Litt MD, Kadden RM, Petry NM,. Behavioral treatment for marijuana dependence: randomized trial of contingency management and self-efficacy enhancement. Addict Behav 2013; 3: 1764-75.
16. Stephens RS, Roffman RA, Simpson EE,. Treating adult marijuana dependence: a test of the relapse prevention model. J Consult Clin Psychol 1994; 1: 92-9.
17. Marlatt GAG Jr,. Relapse prevention: maintenance strategies in the treatment of addictive behaviors. New York: Guilford Press; 1985.
18. Stephens RS, Roffman RA, Curtin L,. Comparison of extended versus brief treatments for marijuana use. J Consult Clin Psychol 2000; 5: 898-908.
19. Copeland J, Swift W, Roffman R, Stephens R,. A randomized controlled trial of brief cognitive-behavioral interventions for cannabis use disorder. J Subst Abuse Treat 2001; 2: 55-64.
20. Miller WR, Rollnick S,. Motivational interviewing: helping people change, 3rd ed. New York: Guilford Press; 2013.
21. Stephens RS, Roffman RA, Fearer SA, Williams C, Burke RS,. The Marijuana Check-up: promoting change in ambivalent marijuana users. Addiction 2007; 6: 947-57.
22. Stephens RS, Roffman RA, Fearer SA, Williams C, Picciano JF, Burke RS,. The Marijuana Check-up: reaching users who are ambivalent about change. Addiction 2004; 10: 1323-32.
23. Miller WR, Benefield GS, Tonigan JS,. Enhancing motivation for change in problem drinking: a controlled comparison of two therapist styles. J Consult Clin Psychol 1993; 61: 455-61.
24. Miller WR, Sovereign RG,. The check-up: a model for early intervention in addictive behaviors. In:, Loberg T, Miller WR, Nathan PE, Marlatt GA, eds. Addictive behaviors: prevention and early intervention. Amsterdam: Swets & Zeitlinger, 1989: 219-31.
25. Miller WR, Sovereign RG, Krege B,. Motivational Interviewing with problem drinkers: II. The drinkers check-up as a preventive intervention. Behav Psychother 1988; 16: 251-68.
26. Martin G, Copeland J,. The adolescent cannabis check-up: randomized trial of a brief intervention for young cannabis users. J Subst Abuse Treat 2008; 4: 407-14.
27. de Gee EA, Verdurmen JEE, Bransen E, de Jonge JM, Schippers GM,. A randomized controlled trial of a brief motivational enhancement for non-treatment-seeking adolescent cannabis users. J Subst Abuse Treat 2014; 3: 181-8.
28. McCambridge J, Slym RL, Strang J,. Randomized controlled trial of motivational interviewing compared with drug information and advice for early intervention among young cannabis users. Addiction 2008; 11: 1809-18.
29. McCambridge J, Day M, Thomas BA, Strang J,. Fidelity to Motivational Interviewing and subsequent cannabis cessation among adolescents. Addict Behav 2011; 7: 749-54.
30. Flory K, Lynam D, Milich R, Leukefeld C, Clayton R,. Early adolescent through young adult alcohol and marijuana use trajectories: early predictors, young adult outcomes, and predictive utility. Dev Psychopathol 2004; 1: 193-213.
31. Brady KT, Randall CL,. Gender differences in substance use disorders. Psychiatr Clin North Am 1999; 2: 241-52.
32. Greenfield SF, Manwani SG, Nargiso JE,. Epidemiology of substance use disorders in women. Obstet Gynecol Clin North Am 2003; 3: 414-46.
33. Stein MD, Hagerty CE, Herman DS, Phipps MG, Anderson BJ,. A brief marijuana intervention for non-treatment-seeking young adult women. J Subst Abuse Treat 2011; 2: 189-98.
34. Dennis M, Godley SH, Diamond G, et al., The Cannabis Youth Treatment (CYT) Study: main findings from two randomized trials. J Subst Abuse Treat 2004; 3: 197-213.
35. Walker DD, Stephens RS, Towe S, Banes K, Roffman R,. Maintenance check-ups following treatment for cannabis dependence. J Subst Abuse Treat 2015; 56: 11-15.
36. Carroll KM, Easton CJ, Nich C, et al., The use of contingency management and motivational/skills-building therapy to treat young adults with marijuana dependence. J Consult Clin Psychol 2006; 5: 955-66.
37. Liddle HA, Dakof GA, Turner RM, Henderson CE, Greenbaum PE,. Treating adolescent drug abuse: a randomized trial comparing multidimensional family therapy and cognitive behavior therapy. Addiction 2008; 10: 1660-70.
38. Hendriks V, van der Schee E, Blanken P,. Treatment of adolescents with a cannabis use disorder: main findings of a randomized controlled trial comparing multidimensional family therapy and cognitive behavioral therapy in The Netherlands. Drug Alcohol Depend 2011; 1-2: 64-71.
39. de Dios MA, Herman DS, Britton WB, Hagerty CE, Anderson BJ, Stein MD,. Motivational and mindfulness intervention for young adult female marijuana users. J Subst Abuse Treat 2012; 1: 56-64.
40. Kay-Lambkin FJ, Baker AL, Lewin TJ, Carr VJ,. Computer-based psychological treatment for comorbid depression and problematic alcohol and/or cannabis use: a randomized controlled trial of clinical efficacy. Addiction 2009; 3: 378-88.
41. Kay-Lambkin F, Baker A, Kelly B, Lewin T,. Clinician assisted computerized versus therapist delivered treatment for depressive and addictive disorders: a randomized controlled trial. Med J Aust 2011; 195: S44-50.
42. Budney AJ, Fearer S, Walker DD, et al., An initial trial of a computerized behavioral intervention for cannabis use disorder. Drug Alcohol Depend 2011; 1-2: 74-9.
43. Tossmann HP, Jonas B, Tensil MD, Lang P, Struber E,. A controlled trial of an internet-based intervention program for cannabis users. Cyberpsychol Behav Soc Netw 2011; 11: 673-9.
44. Rooke S, Copeland J, Norberg M, Hine D, McCambridge J,. Effectiveness of a self-guided web-based cannabis treatment program: randomized controlled trial. J Med Inter Res 2013; 2: e26.
45. Budney AJ, Stanger C, Tilford JM, et al., Computer-assisted behavioral therapy and contingency management for cannabis use disorder. Psychol Addict Behav 2015; 29: 501-11.
46. Budney AJ, Hughes JR,. The cannabis withdrawal syndrome. Curr Opin Psychiatry 2006; 3: 233-8.
47. Haney M, Ward AS, Comer SD, Hart CL, Foltin RW, Fischman MW,. Bupropion SR worsens mood during marijuana withdrawal in humans. Psychopharmacology 2001; 2: 171-9.
48. Penetar DM, Looby AR, Ryan ET, Maywalt MA, Lukas SE,. Bupropion reduces some of the symptoms of marihuana withdrawal in chronic marihuana users: a pilot study. Subst Abuse 2012; 6: 63-71.
49. Haney M, Hart CL, Ward AS, Foltin RW,. Nefazodone decreases anxiety during marijuana withdrawal in humans. Psychopharmacology 2003; 2: 157-65.
50. Haney M, Hart CL, Vosburg SK, et al., Effects of baclofen and mirtazapine on a laboratory model of marijuana withdrawal and relapse. Psychopharmacology 2010; 2: 233-44.
51. Haney M, Hart CL, Vosburg SK, et al., Marijuana withdrawal in humans: effects of oral THC or divalproex. Neuropsychopharmacology 2004; 1: 158-70.
52. Budney AJ, Vandrey RG, Hughes JR, Moore BA, Bahrenburg B,. Oral delta-9-tetrahydrocannabinol suppresses cannabis withdrawal symptoms. Drug Alcohol Depend 2007; 1: 22-9.
53. Haney M, Hart CL, Vosburg SK, Comer SD, Reed SC, Foltin RW,. Effects of THC and lofexidine in a human laboratory model of marijuana withdrawal and relapse. Psychopharmacology 2008; 1: 157-68.
54. Haney M, Cooper ZD, Bedi G, Vosburg SK, Comer SD, Foltin RW,. Nabilone decreases marijuana withdrawal and a laboratory measure of marijuana relapse. Neuropsychopharmacology 2013; 38: 1557-65.
55. Winstock AR, Lea T, Copeland J,. Lithium carbonate in the management of cannabis withdrawal in humans: an open-label study. J Psychopharmacol 2009; 1: 84-93.
56. Johnston J, Lintzeris N, Allsop DJ, et al., Lithium carbonate in the management of cannabis withdrawal: a randomized placebo-controlled trial in an inpatient setting. Psychopharmacology 2014; 231: 4623-36.
57. Vandrey R, Smith MT, McCann UD, Budney AJ, Curran EM,. Sleep disturbance and the effects of extended-release zolpidem during cannabis withdrawal. Drug Alcohol Depend 2011; 1: 38-44.
58. Cooper ZD, Foltin RW, Hart CL, Vosburg SK, Comer SD, Haney M,. A human laboratory study investigating the effects of quetiapine on marijuana withdrawal and relapse in daily marijuana smokers. Addict Biol 2013; 6: 993-1002.
59. Carroll KM, Kosten TR, Rounsaville BJ,. Choosing a behavioral therapy platform for pharmacotherapy of substance users. Drug Alcohol Depend 2004; 2: 123-34.
60. Carpenter KM, McDowell D, Brooks DJ, Cheng WY, Levin FR,. A preliminary trial: double-blind comparison of nefazodone, bupropion-SR, and placebo in the treatment of cannabis dependence. Am J Addict 2009; 1: 53-64.
61. Weinstein AM, Miller H, Bluvstein I, et al., Treatment of cannabis dependence using escitalopram in combination with cognitive-behavior therapy: a double-blind placebo-controlled study. Am J Drug Alcohol Abuse 2014; 1: 16-22.
62. McRae AL, Brady KT, Carter RE,. Buspirone for treatment of marijuana dependence: a pilot study. Am J Addict 2006; 5: 404.
63. McRae-Clark AL, Carter RE, Killeen TK, et al., A placebo-controlled trial of buspirone for the treatment of marijuana dependence. Drug Alcohol Depend 2009; 1-2: 132-8.
64. McRae-Clark AL, Baker NL, Gray KM, et al., Buspirone treatment of cannabis dependence: a randomized, placebo-controlled trial. Drug Alcohol Depend 2015; 156: 29-37.
65. Marshall K, Gowing L, Ali R, Le Foll B,. Pharmacotherapies for cannabis dependence. Cochrane Database Syst Rev 2014; 12: CD008940.
66. Levin FR, Mariani JJ, Brooks DJ, Pavlicova M, Cheng W, Nunes EV,. Dronabinol for the treatment of cannabis dependence: a randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend 2011; 1-3: 142-50.
67. Levin FR, McDowell D, Evans SM, et al., Pharmacotherapy for marijuana dependence: a double-blind, placebo-controlled pilot study of divalproex sodium. Am J Addict 2004; 1: 21-32.
68. Mason BJ, Crean R, Goodell V, et al., A proof-of-concept randomized controlled study of gabapentin: effects on cannabis use, withdrawal and executive function deficits in cannabis-dependent adults. Neuropsychopharmacology 2012; 7: 1689-98.
69. Gray KM, Watson NL, Carpenter MJ, Larowe SD,. N-acetylcysteine (NAC) in young marijuana users: an open-label pilot study. Am J Addict 2010; 2: 187-9.
70. Gray KM, Carpenter MJ, Baker NL, et al., A double-blind randomized controlled trial of N-acetylcysteine in cannabis-dependent adolescents. Am J Psychiatry 2012; 8: 805-12.
71. McClure EA, Gipson CD, Malcolm RJ, Kalivas PW, Gray KM,. Potential role of N-acetylcysteine in the management of substance use disorders. CNS Drugs 2014; 2: 95-106.
72. Rounsaville BJ, Anton SF, Carroll K, Budde D, Prusoff BA, Gawin F,. Psychiatric diagnoses of treatment-seeking cocaine abusers. Arch Gen Psychiatry 1991; 1: 43-51.
73. Rounsaville BJ, Weissman MM, Crits-Christoph K, Wilber C, Kleber H,. Diagnosis and symptoms of depression in opiate addicts. Course and relationship to treatment outcome. Arch Gen Psychiatry 1982; 2: 151-6.
74. Strakowski SM, Tohen M, Stoll AL, Faedda GL, Goodwin DC,. Comorbidity in mania at first hospitalization. Am J Psychiatry 1992; 4: 554-6.
75. Brady KT, Sonne SC, Anton R, Ballenger JC,. Valproate in the treatment of acute bipolar affective episodes complicated by substance abuse: a pilot study. J Clin Psychiatry 1995; 3: 118-21.
76. Kranzler HR, Burleson JA, Del Boca FK, et al., Buspirone treatment of anxious alcoholics. A placebo-controlled trial. Arch Gen Psychiatry 1994; 9: 720-31.
77. Nunes EV, Quitkin FM, Donovan SJ, et al., Imipramine treatment of opiate-dependent patients with depressive disorders. A placebo-controlled trial. Arch Gen Psychiatry 1998; 2: 153-60.
78. Stinson FS, Ruan WJ, Pickering R, Grant BF,. Cannabis use disorders in the USA: prevalence, correlates and co-morbidity. Psychol Med 2006; 10: 1447-60.
79. Cornelius JR, Salloum IM, Haskett RF, et al., Fluoxetine versus placebo for the marijuana use of depressed alcoholics. Addict Behav 1999; 1: 111-4.
80. Cornelius JR, Bukstein OG, Douaihy AB, et al., Double-blind fluoxetine trial in comorbid MDD-CUD youth and young adults. Drug Alcohol Depend 2010; 1-2: 39-45.
81. Levin FR, Mariani J, Brooks DJ, et al., A randomized double-blind, placebo-controlled trial of venlafaxine-extended release for co-occurring cannabis dependence and depressive disorders. Addiction 2013; 6: 1084-94.
82. McRae-Clark AL, Carter RE, Killeen TK, Carpenter MJ, White KG, Brady KT,. A placebo-controlled trial of atomoxetine in marijuana-dependent individuals with attention deficit hyperactivity disorder. Am J Addict 2010; 6: 481-9.
83. Marsch LA, Carroll KM, Kiluk BD,. Technology-based interventions for the treatment and recovery management of substance use disorders: a JSAT special issue. J Subst Abuse Treat 2014; 1: 1-4.
84. Corkrey R, Parkinson L,. Interactive voice response: review of studies 1989-2000. Behav Res Methods 2002; 3: 342-53.
85. Searles JS, Helzer JE, Rose GI, et al., Concurrent and retrospective reports of alcohol consumption across 30, 90, and 366 days: interactive voice response compared with the timeline follow back. J Stud Alcohol 2002; 63: 352-62.
86. Rose GL, Skelly JM, Badger GJ, Ferraro TA, Helzer JE,. Efficacy of automated telephone continuing care following outpatient therapy for alcohol dependence. Addict Behav 2015; 41: 223-31.
87. Naylor MR, Keefe FJ, Brigidi B, et al., Therapeutic interactive voice response for chronic pain reduction and relapse prevention. Pain 2008; 3: 335-45.
88. Buckner JD, Crosby RD, Silgado J, Wonderlich SA, Schmidt NB,. Immediate antecedents of marijuana use: an analysis from ecological momentary assessment. J Behav Ther Exp Psychiatry 2012; 1: 647-55.
89. Buckner JD, Crosby RD, Wonderlich SA, Schmidt NB,. Social anxiety and cannabis use: an analysis from ecological momentary assessment. J Anxiety Disord 2012; 2: 297-304.
90. Shrier LA, Rhoads A, Burke P, Walls C, Blood EA,. Real-time, contextual intervention using mobile technology to reduce marijuana use among youth: a pilot study. Addict Behav 2014; 1: 173-80.
91. Group PMR. Matching alcoholism treatments to client heterogeneity: Project MATCH Posttreatment drinking outcomes. J Stud Alcohol 1997; 1: 7-29.
92. Group PMR. Matching alcoholism treatments to client heterogeneity: project MATCH three-year drinking outcomes. Alcoholism 1998; 6: 1300-11.
93. Carroll KM, Kiluk BD, Nich C, et al., Computer-assisted delivery of cognitive-behavioral therapy: efficacy and durability of CBT4CBT among cocaine-dependent individuals maintained on methadone. Am J Psychiatry 2014; 171: 436-44.
94. Dutra L, Stathopoulou G, Basden SL, Leyro TM, Powers MB, Otto MW,. A meta-analytic review of psychosocial interventions for substance use disorders. Am J Psychiatry 2008; 165: 179-87.
95. Nuijten M, Blanken P, van den Brink W, Hendriks V,. Treatment of crack-cocaine dependence with topiramate: a randomized controlled feasibility trial in the Netherlands. Drug Alcohol Depend 2014; 138: 177-84.
96. Tapp A, Wood AE, Kennedy A, Sylvers P, Kilzieh N, Saxon AJ,. Quetiapine for the treatment of cocaine use disorder. Drug Alcohol Depend 2015; 149: 18-24.
97. Budney AJ, Radonovich KJ, Higgins ST, et al., Adults seeking treatment for marijuana dependence: a comparison with cocaine-dependent treatment seekers. Exp Clin Psychopharmacol 1998; 6: 419-26.
98. Ellingstad TP, Sobell LC, Sobell MB, Eickleberry L, Golden CJ,. Self-change: a pathway to cannabis abuse resolution. Addict Behav 2006; 31: 519-30.
99. Gates P, Copeland J, Swift W, Martin G,. Barriers and facilitators to cannabis treatment. Drug Alcohol Rev 2012; 31: 311-9.
100. van der Pol P, Liebregts N, de Graaf R, Korf DJ, van den Brink W, van Laar M,. Facilitators and barriers in treatment seeking for cannabis dependence. Drug Alcohol Depend 2013 Dec 1; 133 (2): 776-80.